Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
Diabetes
United Labs Gains NMPA Approval for Ozempic Biosimilar IND
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...
Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014
China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...
Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes
China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...
Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd...
Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial
China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...
Boehringer, Eli Lilly’s Jardiance Wins NMPA Approval for Heart Failure with Preserved Ejection Fraction
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) announced that China’s National Medical Products Administration (NMPA)...
CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...
Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...
Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...
Structure Therapeutics Oversubscribes USD33m on Top of USD100m Series B Round
Structure Therapeutics, a Sino-US firm formerly known as ShouTi Inc., announced the oversubscription of USD33...
Sciwind Biosciences’ XW003 Hits Phase II Trial Goals in Type 2 Diabetes Treatment
Hangzhou-based biopharma Sciwind Biosciences Co., Ltd announced positive results from a 20-week Phase II trial...
Eli Lilly Files for Baqsimi Approval in China to Treat Severe Hypoglycemia
Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center...
Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion
France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3...
Hybio Pharmaceutical’s Liraglutide Filing Accepted by NMPA, Becomes Domestic Leader in GLP-1 Analog
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a...
Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...